AIDS and Behavior

, Volume 11, Issue 4, pp 603–610

The Impact of Chronic Hepatitis C on Health-Related Quality of Life in Homeless and Marginally Housed Individuals with HIV

  • Judith I. Tsui
  • David R. Bangsberg
  • Kathleen Ragland
  • Christopher S. Hall
  • Elise D. Riley
Original Paper

Abstract

Although infection with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) frequently co-exist, there has been little research to determine the effects of HIV/HCV co-infection on health-related quality of life (HRQOL). We performed a cross-sectional analysis of baseline data from 216 participants enrolled in a community based study of HIV-infected homeless and marginally housed individuals, using multivariable linear regression analysis to determine if co-infection with HCV was independently associated with lower short-form 36 (SF-36) questionnaire scores. We found that individuals with HCV had significantly lower mean SF-36 scores in the domains of physical functioning, bodily pain, social functioning and role limitation due to emotional health, and that HIV/HCV co-infection was independently associated with a lower physical component score but not a lower mental component score after controlling for numerous covariates. These results suggest that co-infection with HCV may have an adverse effect on HRQOL among homeless and marginally housed individuals with HIV.

Keywords

Hepatitis C HIV Quality of Life Homelessness 

Abbreviations

HCV

Hepatitis C virus

HRQOL

Health-related quality of life

HIV

Human immunodeficiency virus

SF-36

Short form 36

PCS

Physical component scale

MCS

Mental component scale

HAART

Highly active anti-retroviral therapy

HMH

Homeless/marginally housed

References

  1. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., et al. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341, 556–562.PubMedCrossRefGoogle Scholar
  2. Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E. Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7, 39–55.PubMedCrossRefGoogle Scholar
  3. Call, S. A., Klapow, J. C., Stewart, K. E., Westfall, A. O., Mallinger, A. P., DeMasi, R., et al. (2000). Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research, 9, 977–985.PubMedCrossRefGoogle Scholar
  4. Carrat, F., Bani-Sadr, F., Pol, S., Rosenthal, E., Lunel-Fabiani, F., Benzekri, A., et al. (2004). Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. Journal of the American Medical Association, 292, 2839–2848.PubMedCrossRefGoogle Scholar
  5. Cheung, R. C., Hanson, A. K., Maganti, K., Keeffe, E. B., & Matsui, S. M. (2002). Viral hepatitis and other infectious diseases in a homeless population. Journal of Clinical Gastroenterology, 34, 476–480.PubMedCrossRefGoogle Scholar
  6. Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., et al. (2004). Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351, 451–459.PubMedCrossRefGoogle Scholar
  7. Cordoba, J., Flavia, M., Jacas, C., Sauleda, S., Esteban, J. I., Vargas, V., et al. (2003a). Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology, 39, 231–238.CrossRefGoogle Scholar
  8. Cordoba, J., Reyes, J., Esteban, J. I., & Hernandez, J. M. (2003b). Labeling may be an important cause of reduced quality of life in chronic hepatitis C. American Journal of Gastroenterology, 98, 226–227.Google Scholar
  9. Culhane, D. P., Gollub, E., Kuhn, R., & Shpaner, M. (2001). The co-occurrence of AIDS and homelessness: Results from the integration of administrative databases for AIDS surveillance and public shelter utilisation in Philadelphia. Journal of Epidemiology and Community Health, 55, 515–520.PubMedCrossRefGoogle Scholar
  10. Fleming, C. A., Craven, D. E., Thornton, D., Tumilty, S., & Nunes, D. (2003). Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clinical Infectious Diseases, 36, 97–100.PubMedCrossRefGoogle Scholar
  11. Fontana, R. J., Hussain, K. B., Schwartz, S. M., Moyer, C. A., Su, G. L., & Lok, A. S. (2002). Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Journal of Hepatology, 36, 401–407.PubMedCrossRefGoogle Scholar
  12. Forton, D. M., Taylor-Robinson, S. D., & Thomas, H. C. (2003). Cerebral dysfunction in chronic hepatitis C infection. Journal of Viral Hepatitis, 10, 81–86.PubMedCrossRefGoogle Scholar
  13. Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27, 209–212.PubMedCrossRefGoogle Scholar
  14. Gallegos-Orozco, J. F., Fuentes, A. P., Gerardo Argueta, J., Perez-Pruna, C., Hinojosa-Becerril, C., Sixtos-Alonso, M. S., et al. (2003). Health-related quality of life and depression in patients with chronic hepatitis C. Archivesof Medical Research, 34, 124–129.CrossRefGoogle Scholar
  15. Gill, C. J., Griffith, J. L., Jacobson, D., Skinner, S., Gorbach, S. L., & Wilson, I. B. (2002). Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. Journal of Acquired Immune Deficiency Syndrome, 30, 485–492.Google Scholar
  16. Hall, C. S., Charlebois, E. D., Hahn, J. A., Moss, A. R., & Bangsberg, D. R. (2004). Hepatitis C virus infection in San Francisco’s HIV-infected urban poor. Journal of General Internal Medicine, 19, 357–365.PubMedCrossRefGoogle Scholar
  17. Hays, R. D., Cunningham, W. E., Sherbourne, C. D., Wilson, I. B., Wu, A. W., Cleary, P. D., et al. (2000). Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization Study. American Journal of Medicine, 108, 714–722.PubMedCrossRefGoogle Scholar
  18. Hays, R. D., & Woolley, J. M. (2000). The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics, 18, 419–423.PubMedCrossRefGoogle Scholar
  19. Hilsabeck, R. C., Hassanein, T. I., Carlson, M. D., Ziegler, E. A., & Perry, W. (2003). Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. Journal- International Neuropsychological Society, 9, 847–854.CrossRefGoogle Scholar
  20. Hunt, C. M., Dominitz, J. A., Bute, B. P., Waters, B., Blasi, U., & Williams, D. M. (1997). Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Digestive Diseases and Sciences, 42, 2482–2486.PubMedCrossRefGoogle Scholar
  21. Kanwal, F., Gralnek, I. M., Hays, R. D., Dulai, G. S., Spiegel, B. M., Bozzette, S., et al. (2005). Impact of chronic viral hepatitis on health-related quality of life in HIV: Results from a nationally representative sample. American Journal of Gastroenterology, 100, 1984–1994.PubMedCrossRefGoogle Scholar
  22. Kramer, L., Bauer, E., Funk, G., Hofer, H., Jessner, W., Steindl-Munda, P., et al. (2002). Subclinical impairment of brain function in chronic hepatitis C infection. Journal of Hepatology, 37, 349–354.PubMedCrossRefGoogle Scholar
  23. Laguno, M., Murillas, J., Blanco, J. L., Martinez, E., Miquel, R., Sanchez-Tapias, J. M., et al. (2004). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS, 18, F27–F36.PubMedCrossRefGoogle Scholar
  24. McHutchison, J. G., Ware, J. E. Jr., Bayliss, M. S., Pianko, S., Albrecht, J. K., Cort, S., et al. (2001). The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. Journal of Hepatology, 34, 140–147.PubMedCrossRefGoogle Scholar
  25. Nyamathi, A. M., Dixon, E. L., Robbins, W., Smith, C., Wiley, D., Leake, B., et al. (2002). Risk factors for hepatitis C virus infection among homeless adults. Journal of General Internal Medicine, 17, 134–143.PubMedCrossRefGoogle Scholar
  26. Riley, E. D., Bangsberg, D. R., Perry, S., Clark, R. A., Moss, A. R., & Wu, A. W. (2003). Reliability and validity of the SF-36 in HIV-infected homeless and marginally housed individuals. Quality of Life Research, 12, 1051–1058.PubMedCrossRefGoogle Scholar
  27. Robertson, M. J., Clark, R. A., Charlebois, E. D., Tulsky, J., Long, H. L., Bangsberg, D. R., et al. (2004). HIV seroprevalence among homeless and marginally housed adults in San Francisco. American Journal of Public Health, 94, 1207–1217.PubMedCrossRefGoogle Scholar
  28. Rowan, P. J., Tabasi, S., Abdul-Latif, M., Kunik, M. E., & El-Serag, H. B. (2004). Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. Journal of Clinical Gastroenterology, 38, 530–534.PubMedCrossRefGoogle Scholar
  29. Samsa, G., Edelman, D., Rothman, M. L., Williams, G. R., Lipscomb, J., & Matchar, D. (1999). Determining clinically important differences in health status measures: A general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics, 15, 141–155.PubMedCrossRefGoogle Scholar
  30. Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41, 790–800.PubMedCrossRefGoogle Scholar
  31. Sulkowski, M. S., & Thomas, D. L. (2003). Hepatitis C in the HIV-Infected Person. Annals of Internal Medicine, 138, 197–207.PubMedGoogle Scholar
  32. Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., et al. (2004). Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351, 438–450.PubMedCrossRefGoogle Scholar
  33. Vittinghoff, E., Glidden, D. V., Shiboski, S. C., & McCulloch, C. E. (2005). Regression Methods in Biostatistics. New York, NY: Springer (p. 94).Google Scholar
  34. Ware, J. E. Jr., Kosinski, M., Bayliss, M. S., McHorney, C. A., Rogers, W. H., & Raczek, A. (1995). Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Medical Care, 33, AS264–AS279.PubMedCrossRefGoogle Scholar
  35. Ware, J. E. Jr., Kosinski, M., & Gandek, B. (2004). SF-36 Health Survey Manual & Interpretation Guide. QualityMetric Incorporated, Lincoln, RI.Google Scholar
  36. Wu, A. W., Hays, R. D., Kelly, S., Malitz, F., & Bozzette, S. A. (1997). Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Quality of Life Reserch, 6, 531–554.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Judith I. Tsui
    • 1
  • David R. Bangsberg
    • 2
    • 3
  • Kathleen Ragland
    • 2
  • Christopher S. Hall
    • 3
    • 4
  • Elise D. Riley
    • 2
  1. 1.San Francisco Veterans Administration Medical CenterUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General HospitalUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Positive Health ProgramSan Francisco General HospitalSan FranciscoUSA
  4. 4.STD Control Branch, California Department of Health ServicesCalifornia STD/HIV Prevention Training CenterCaliforniaUSA

Personalised recommendations